Premier Breakthroughs 24 just wrapped up in National Harbor, Maryland. If we didn’t get to meet you at this event, learn more about our oncology solutions online: https://lnkd.in/gJH7swsP Thank you!
NeoGenomics Laboratories’ Post
More Relevant Posts
-
If you are a member of AAPM, you might check out the upcoming webinar on digital twins by Jun Deng, "Enabling Digital Twins for Predictive Oncology". For more information on this (and all previous and upcoming AAPM webinars), head on over to: https://lnkd.in/gXFq3jfY.
To view or add a comment, sign in
-
Going to American Society of Clinical Oncology (ASCO) in Chicago this week and next? You may find our latest blog helpful. Give us a shout when you're here. connect@hdmz.com
Unlock the Potential of ASCO: A Beginner’s Journey Through Chicago's Premier Oncology Conference. Dive into our comprehensive guide to navigating #ASCO. From pre-planning travel to post-conference reflection and a dash of Chicago charm, all of our tips and tricks are in one place! Swipe through below and read more in our blog at: https://lnkd.in/gaC4Zp5C #ASCO2024
To view or add a comment, sign in
-
Medical Sales Director with expertise in IDNs, GPOs, and community practices, driving revenue growth and optimizing market access through strategic relationships and effective reimbursement strategies.
🩺💼 Cardinal Health Acquires Integrated Oncology Network (ION)🌐💰 💡 What's happening? Cardinal Health is acquiring Integrated Oncology Network (ION) for $1.115B 💵, expanding their Navista oncology practice alliance. ION operates more than 50 community-based oncology sites across 10 states, adding 100+ providers to the Cardinal Health family. 🔬 What does it mean for healthcare? This acquisition strengthens Cardinal Health's oncology services, offering advanced technology, AI-driven analytics, and practice management tools to support independent community practices. It’s a big move in specialty care, ensuring better access to oncology and urology services for patients across the U.S. 🏥 Impact on competition: - Cardinal Health is positioning itself as a leader in community oncology with this acquisition. Their Navista platform is becoming a comprehensive solution for oncology practices, rivaling McKesson** (McKesson ) and Cencora (Cencora in specialty care. - With access to AI, deep analytics, and a larger provider base, Cardinal is enhancing its ability to support value-based care, competing aggressively in the oncology space against its peers. This could also pressure competitors to invest in AI and analytics for better patient outcomes. 🔗 Outlook: This acquisition is a strategic push for Cardinal Health, enhancing its presence in the oncology field and helping independent practices stay competitive 💪. It also strengthens Cardinal's supply chain for specialty pharmaceuticals. Expect this move to pay off after 12 months 📈, further solidifying Cardinal's foothold in the oncology market. Hashtags: #CardinalHealth #ION #OncologyAcquisition #HealthcareTech #PharmaIndustry #SpecialtyCare #AIInHealthcare
We have entered into an agreement to acquire Integrated Oncology Network (ION). Together, we will advance our shared mission of helping community oncology practices accelerate growth and secure their independence while providing world-class, patient-centered care. Read the full announcement here: https://lnkd.in/gTPX6R8t
To view or add a comment, sign in
-
Did your organization apply for the reopened Enhancing Oncology Model (EOM)? In a recent Canopy webinar, thought leaders from CMS and community oncology shared helpful insights and strategies for success in the EOM and other value-based programs. Catch the full discussion to learn more: https://lnkd.in/ekfjd6V4
To view or add a comment, sign in
-
Is your site considering phase 1 oncology trials? SCRS has a guide that outlines several major considerations a site should explore when considering these types of trials. Access it here ⇢ https://lnkd.in/gBqrX2TX
To view or add a comment, sign in
-
Is your site considering phase 1 oncology trials? SCRS has a guide that outlines several major considerations a site should explore when considering these types of trials. Access it here ⇢ https://lnkd.in/gBqrX2TX
To view or add a comment, sign in
-
Come learn about how our data marketplace is powering more precise and effective pharma marketing!
Just a few more days until Digital Pharma East 2024! The Prognos team would love to connect and share more about our new offerings in rare disease, oncology, and media. Drop by booth K1 or book a time to connect here: https://bit.ly/3XAfcIo Christopher N. Hayes, Andrew Mataraso, Steven Vitale, and Jim Dietz look forward to seeing you there! #dpeast #rwd #healthcareinnovation
To view or add a comment, sign in
-
Oncology never ceases to be top of mind for our clients. This paper provides a primer on valuation issues related to oncology services. https://lnkd.in/e_85k5mh
To view or add a comment, sign in
-
Satej Bhogill and Catherine Chintala, PMP share what they enjoyed most at this year's #ASCO24 conference. Learn more about MERIT's oncology experience and solutions at https://lnkd.in/gD7rC9zQ #MERITCRO #YourClinicalEndpointExpert #imagingsolutions #clinicaltrials #clincialresearch #oncologytrials
ASCO 2024 Recap
To view or add a comment, sign in
33,399 followers